Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Fennec to $17 from $20 and keeps a Buy rating on the shares. The firm notes Fennec delivered a slower quarter than expected, with Pedmark revenues of $7.4M vs Street’s $10.2M. Craig-Hallum’s biggest takeaways from the quarter include slower Pediatric growth until the compounding issue is addressed, and FENC shifting focus onto AYA, where incentives are aligned from a reimbursement perspective.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FENC:
- Fennec Pharmaceuticals Sees Robust Q1 Growth
- Fennec reports Q1 EPS 41c, consensus 26c
- Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- FENC Upcoming Earnings Report: What to Expect?
- Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024